Biotech lead generation that finds decision-makers.
BeReach reads the public signals biotech and pharma companies leave behind, like funding rounds, clinical trial milestones, partnerships and hiring. It qualifies each company against your ICP, then helps you reach the right decision-maker with a warm, contextual message.
1,000+ teams4.9| # | Name | Conn | Signal |
|---|---|---|---|
| 1 |  Dr Helena Voss VP Clinical Development · Seralyn Bio | 2nd | Liked the post |
| 2 |  Nathan Frost Head of Business Development · Aximia Therapeutics | 2nd | Commented |
| 3 |  Priyanka Menon Director of R&D · Novexa Labs | 3rd | Commented |
| 4 | Oliver Grant Founder · Cellwave Bio | 2nd | Reposted |
| 5 | Sara Lindqvist Program Manager · Halden Pharma | 3rd | Liked the post |
Biotech and pharma signals
funding, trials, partnerships, hiring
Typical acceptance rate
warm, contextual first touch
Typical reply rate
vs generic cold outreach
To a qualified list
any modality, any stage
Your agent scans where these accounts actually show up: funding and launch data, reviews and traction, tech stacks, hiring posts, and the people behind them.
Every account is scored against your ideal profile on size, stage, traction and buying signals, so noise is filtered out before it ever reaches you.
For each qualified account, the agent finds the right decision-maker and helps you send a contextual message that references a real signal, not a generic template.
Know exactly when a biotech raises, who led it, and how much. A freshly funded team is actively buying services, tools and partners, so you can reach them while the budget is fresh.
Phase progress and enrollment updates in public registries mark a program advancing. Reach clinical and operations leads while priorities and needs are shifting.
Research, licensing and co-development deals show a company opening up its stack. Lead with a reason tied to their newest partnership, not a cold pitch.
A company posting clinical, regulatory or business development roles is scaling a program. Track hiring to find teams in active growth mode.
BeReach reads the public web in real time, across funding data, public clinical trial registries, partnership announcements, job boards and public profiles, then cross-references them to surface qualified companies along with the actual decision-maker's name and how to reach them. It is live signal, not a quarterly database dump.
Legacy databases index enterprise firmographics and refresh slowly, so early therapeutics startups and specialized services vendors are under-covered or missing entirely. BeReach searches the real-time sources where biotech and pharma companies actually surface, like funding, trial milestones, partnerships and hiring, so it finds accounts those databases do not have.
Yes. Every lead is built from public signals across the open web, including public trial registries, cross-referenced and verified. There is no scraping behind a login and no private database, and targeting is B2B, focused on business decision-makers.
Funding stage and recency, clinical trial phase and milestones, partnerships and licensing deals, headcount and hiring activity. You describe your ICP in plain language and the agent scores each company against it, so only the strong-fit ones reach you.
Yes, and that is the difference from a list tool. After the Finder surfaces companies and the Qualifier scores them, the Reacher helps you open a warm, multichannel conversation with the right person, referencing a real signal like a recent raise or a Phase 2 milestone instead of a generic template.
Yes. Just describe what you want, like a biotech that advanced to Phase 2 hiring a Head of Clinical Operations in the US, and the agent handles the combination of modality, phase, role and buying signals. No filters or boolean syntax to learn.
Usually under two minutes. Describe the companies you want, the agent scans the public sources, qualifies them against your ICP, and returns a list with named decision-makers ready to reach out to.
The all-in-one AI SDR was supposed to replace your sales team. By early 2026, most companies that tried it have gone back to hybrid models. Here's what AI agents actually do well for LinkedIn prospecting - and where the hype still outpaces reality.
Alexandre Sarfati
Companies doing LinkedIn ABM well generate $10+ in pipeline per dollar spent and 44% higher ROAS than Google. But most ABM on LinkedIn fails because teams treat it like targeted cold outreach. Here's what the data shows actually works.
Alexandre Sarfati
Belkins analyzed over 20 million LinkedIn outreach attempts across 13,000 accounts. Here's what the data says about cold versus warm approaches, which combinations work, and what most teams get wrong.
Alexandre Sarfati
Describe your ideal biotech or pharma account and let your agent find, qualify, and reach the decision-makers behind it.
Free credits inside · no credit card
Click a button and let your favorite AI weigh in.
